

Angiomax - (250 mg/Vial; Injectable, Intravenous)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Bivalirudin | Innovator | Medicines co. |
| Dosage | 250 mg/Vial; Injectable, Intravenous | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | None | Tentative Approvals | Less Than 5 |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | Indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.